Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Anna S. Tocheva"'
Autor:
Michael S. Breen, Xuanjia Fan, Tess Levy, Rebecca M. Pollak, Brett Collins, Aya Osman, Anna S. Tocheva, Mustafa Sahin, Elizabeth Berry-Kravis, Latha Soorya, Audrey Thurm, Craig M. Powell, Jonathan A. Bernstein, Alexander Kolevzon, Joseph D. Buxbaum, Simon K. Warfield, Benoit Scherrer, Rajna Filip-Dhima, Kira Dies, Paige Siper, Ellen Hanson, Jennifer M. Phillips
Publikováno v:
HGG Advances, Vol 4, Iss 1, Pp 100145- (2023)
Summary: Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused at least in part by haploinsufficiency of the SHANK3 gene, due to sequence variants in SHANK3 or subtelomeric 22q13.3 deletions. Phenotypic differences have been rep
Externí odkaz:
https://doaj.org/article/3468f77f03d1418b9e1044467e8fe3e3
Publikováno v:
iScience, Vol 24, Iss 9, Pp 103020- (2021)
Summary: Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1 primarily do not proliferate; however, there is a
Externí odkaz:
https://doaj.org/article/ad4611e681ec4299af2a0f3e9580172c
Autor:
Anna S. Tocheva, Johanna M.C. Jefferies, Myron Christodoulides, Saul N. Faust, Stuart C. Clarke
Publikováno v:
Emerging Infectious Diseases, Vol 16, Iss 1, Pp 154-155 (2010)
Externí odkaz:
https://doaj.org/article/f78bbca4eb5e4eda8dfcac67c1bc1072
Publikováno v:
Immunol Lett
Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity but many patients do not respond and a significant proportion develops inflammatory toxicities. To develop better therapeutics and to understand
Autor:
Michael S. Breen, Xuanjia Fan, Tess Levy, Rebecca Pollak, Brett Collins, Aya Osman, Anna S. Tocheva, Mustafa Sahin, Elizabeth Berry-Kravis, Latha Soorya, Audrey Thurm, Craig M. Powell, Jonathan A. Bernstein, Alexander Kolevzon, Joseph D. Buxbaum
Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused at least in part by haploinsufficiency of the SHANK3 gene, due to sequence variants in SHANK3 or subtelomeric 22q13.3 deletions. Phenotypic differences have been reported bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d6a8b99de8c5e50c7d5962ad1c8eb23
https://doi.org/10.1101/2022.07.06.22277334
https://doi.org/10.1101/2022.07.06.22277334
Autor:
Elliot A. Philips, Benjamin G. Neel, Beatrix Ueberheide, Kieran Adam, Anna S. Tocheva, Marianne Strazza, Adam Mor, Inbar Azoulay-Alfaguter, Shalom Lerrer, Connor Foster, Michael Peled, Shruti Nayak
Publikováno v:
The Journal of Biological Chemistry
Programmed cell death protein 1 (PD-1) is a critical inhibitory receptor that limits excessive T cell responses. Cancer cells have evolved to evade these immunoregulatory mechanisms by upregulating PD-1 ligands and preventing T cell–mediated anti-t
Publikováno v:
Immunology
Ligation of the inhibitory receptor PD‐1 on T cells results in the inhibition of numerous cellular functions. Despite the overtly inhibitory outcome of PD‐1 signalling, there are additionally a collection of functions that are activated. We have
Autor:
Anna S. Tocheva, Adam Mor, Marianne Strazza, Irving E. Vega, Matthew A. Dragovich, Kieran Adam, Michael Peled
Publikováno v:
The Journal of Immunology. 201:2824-2831
Programmed cell death 1 (PD-1) is a major coinhibitory receptor and a member of the immunological synapse (IS). To uncover proteins that regulate PD-1 recruitment to the IS, we searched for cytoskeleton-related proteins that also interact with PD-1 u
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0246168 (2021)
PLoS ONE
PLoS ONE
Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust animal model exists of checkp
Publikováno v:
Curr Protoc Immunol
Our understanding of programmed cell death 1 (PD-1) biology is limited due to technical difficulties in establishing reproducible, yet simple, in vitro assays to study PD-1 signaling in primary human T cells. The protocols in this article were refine